Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (26)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Snyderwine, E. G.
Right arrow Articles by Roberts-Thomson, S. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Snyderwine, E. G.
Right arrow Articles by Roberts-Thomson, S. J.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Carcinogenesis, Vol 19, 1209-1215, Copyright © 1998 by Oxford University Press


ARTICLES

Proliferation, development and DNA adduct levels in the mammary gland of rats given 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine and a high fat diet

EG Snyderwine, CD Davis, HA Schut and SJ Roberts-Thomson
Chemical Carcinogenesis Section, Laboratory of Experimental Carcinogenesis, Division of Basic Sciences, National Cancer Institute, NIH, Bethesda, MD 20892-4255, USA.

2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) is a heterocyclic amine derived from cooked meat that is a mammary gland carcinogen in rats. A carcinogenic dose-regimen of PhIP (75 mg/kg, p.o., 10 doses, once per day) was administered to 43-day old female Sprague-Dawley rats, and the rats were then placed on a defined high fat (23.5% corn oil) or low fat (5% corn oil) diet for up to 6 weeks. At various times after carcinogen and diet, and prior to carcinogenesis, we examined the percentage of proliferating cells in terminal end bud (TEB) epithelial structures of the rat mammary gland by proliferating cell nuclear antigen staining, mammary gland architecture by whole mounting, and PhIP-DNA adduct levels in mammary epithelial cells by the 32P-post-labeling assay. Immediately after dosing, the percentage of proliferating epithelial cells in TEBs was significantly higher in PhIP-treated rats than in control rats receiving vehicle only [7.5 +/- 0.9% (n = 99) versus 4.2 +/- 0.6% (n = 127), respectively]. The mammary glands of PhIP-treated rats showed a significantly lower density of alveolar buds (ABs) and a higher density of TEBs than control rats, which suggests that PhIP exposure partially inhibited the normal glandular differentiation of TEBs to ABs. After 6 weeks on the diet, proliferation in TEBs was statistically higher in rats given PhIP plus a high fat diet than in rats given vehicle plus a low fat diet. The mammary glands from rats on a high fat diet also showed a statistically higher density of TEBs when compared with rats on a low fat diet [2.08 +/- 0.34% versus 1.04 +/- 0.20%, respectively (n = 6)]. PhIP-DNA adduct levels were relatively high in mammary epithelial cells of treated rats. At 3 h after the last dose of PhIP, DNA adduct levels [relative adduct labeling (RAL) x 10(7), mean +/- SE] were 10.5 +/- 1.7 (n = 8) and 0.9 +/- 0.2 (n = 7) in epithelial cells isolated from mammary gland and in the liver, respectively. DNA adduct removal rates from the mammary gland were not different between rats on the high fat and low fat diets. Adducts were still detected after 6 weeks on either diet. Thus, events that occurred prior to neoplasia in the mammary glands of PhIP-treated rats include formation of PhIP-DNA adducts at relatively high levels, and enhanced proliferation in TEBs (putative sites of origin of mammary gland carcinomas) and partial inhibition of TEB differentiation. The high fat diet, a promoter of PhIP-induced mammary gland carcinogenesis, appeared to sustain the proliferative effect of PhIP in mammary gland TEBs at a time when PhIP- DNA adducts are still detectable. These early events may contribute to the targeting and carcinogenicity of PhIP to the mammary gland of rats.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Cancer Res.Home page
S. K. Creton, H. Zhu, and N. J. Gooderham
The Cooked Meat Carcinogen 2-Amino-1-Methyl-6-Phenylimidazo[4,5-b]Pyridine Activates the Extracellular Signal Regulated Kinase Mitogen-Activated Protein Kinase Pathway
Cancer Res., December 1, 2007; 67(23): 11455 - 11462.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
C. Bradley, R. van der Meer, N. Roodi, H. Yan, M. B. Chandrasekharan, Z.-W. Sun, R. L. Mernaugh, and F. F. Parl
Carcinogen-induced histone alteration in normal human mammary epithelial cells
Carcinogenesis, October 1, 2007; 28(10): 2184 - 2192.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
L. Shan, M. Yu, H. A.J. Schut, and E. G. Snyderwine
Susceptibility of Rats to Mammary Gland Carcinogenesis by the Food-Derived Carcinogen 2-Amino-1-Methyl-6-Phenylimidazo[4,5-b]Pyridine (PhIP) Varies with Age and Is Associated with the Induction of Differential Gene Expression
Am. J. Pathol., July 1, 2004; 165(1): 191 - 202.
[Abstract] [Full Text] [PDF]


Home page
MutagenesisHome page
H. Yang, J. Holcroft, B. W. Glickman, and J. G. de Boer
Conjugated linoleic acid inhibits mutagenesis by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine in the prostate of Big Blue(R) rats
Mutagenesis, March 1, 2003; 18(2): 195 - 200.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
M. Yu and E. G. Snyderwine
H-ras oncogene mutations during development of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP)-induced rat mammary gland cancer
Carcinogenesis, December 1, 2002; 23(12): 2123 - 2128.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
E. I. Salim, H. Wanibuchi, K. Morimura, T. Murai, S. Makino, T. Nomura, and S. Fukushima
Induction of tumors in the colon and liver of the immunodeficient (SCID) mouse by 2-amino-3-methylimidazo[4,5-f ]quinoline (IQ)--modulation by long-chain fatty acids
Carcinogenesis, September 1, 2002; 23(9): 1519 - 1529.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
M. Yu, M. L. Jones, M. Gong, R. Sinha, H. A.J. Schut, and E. G. Snyderwine
Mutagenicity of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) in the mammary gland of Big Blue rats on high-and low-fat diets
Carcinogenesis, May 1, 2002; 23(5): 877 - 884.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
M. Xu, G. A. Orner, G. S. Bailey, G. D. Stoner, D. T. Horio, and R. H. Dashwood
Post-initiation effects of chlorophyllin and indole-3-carbinol in rats given 1,2-dimethylhydrazine or 2-amino-3-methyl- imidazo[4,5-f]quinoline
Carcinogenesis, February 1, 2001; 22(2): 309 - 314.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
E. Okochi, N. Watanabe, Y. Shimada, S. Takahashi, K. Wakazono, T. Shirai, T. Sugimura, M. Nagao, and T. Ushijima
Preferential induction of guanine deletion at 5'-GGGA-3' in rat mammary glands by 2-amino- 1-methyl-6-phenylimidazo[4,5-b]pyridine
Carcinogenesis, October 1, 1999; 20(10): 1933 - 1938.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
M. Venugopal, A. Callaway, and E. G. Snyderwine
2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) retards mammary gland involution in lactating Sprague–Dawley rats
Carcinogenesis, July 1, 1999; 20(7): 1309 - 1314.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
H. A.J. Schut and E. G. Snyderwine
DNA adducts of heterocyclic amine food mutagens: implications for mutagenesis and carcinogenesis
Carcinogenesis, March 1, 1999; 20(3): 353 - 368.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.